Sort   by:  
 Page size 
ProteomicsGlycoproteomics Landscape of Asymptomatic and Symptomatic Human Alzheimer's Disease Brain
Alterations of protein abundance and post-translational modifications in patients with Alzheimer’s disease (AD), such as glycosylation, phosphorylation, and ubiquitination, and their roles in disease progression and treatment outcome are areas of intense study. Little is known, however, about...
ORGANISM(S): Homo sapiens (Human) 
2022-10-31 | PXD032219 | Pride
Glycoproteins Mass spectrometry Glycoproteomics Alzheimer's 
UnknownGlycoproteomics Landscape of Asymptomatic and Symptomatic Human Alzheimer's Disease Brain.
Not available
S-EPMC9706167 | biostudies-literature
ProteomicsHuman brain glycoproteomic network alterations in Alzheimer’s disease
We performed a large-scale, site-specific N-glycoproteome profiling study of human Alzheimer’s disease (AD) and control brains using mass spectrometry–based quantitative N-glycoproteomics. The study provided a system-level view of human brain N-glycoproteins and in vivo N-glycosylation sites and ide...
ORGANISM(S): Homo sapiens (Human) 
2022-11-02 | PXD037229 | Pride
Mass spectrometry Glycoproteomics Alzheimer's disease 
ProteomicsGlycoproteomics of Human and Mouse Brains in Alzheimer’s Disease
This study profiles glycoproteomic changes in human frontal cortex and mouse brain in Alzheimer’s disease models. We compare cognitively normal and AD human brain tissue, and wild-type and 5xFAD mouse brain, to define whether AD-associated hyperglycosylation reflects increased glycosylation of exist...
ORGANISM(S): Homo sapiens (Human) 
2026-03-31 | PXD075438 | Pride
Alzheimer’s disease  glycoproteomics  n-glycosylation  human brain  mouse brain 
ProteomicsMultilayered N-glycoproteome Profiling Reveals Highly Heterogeneous and Dysregulated Protein N-glycosylations Related to Alzheimer’s Disease
Protein N-glycosylation is ubiquitous in brain and closely related to cognition and memory. Alzheimer's disease (AD) is a multifactorial disorder that lacks clear pathogenesis and treatment. Aberrant N-glycosylation has been suggested to be involved in AD pathology. While the systematic variations o...
ORGANISM(S): Mus musculus (Mouse) 
2019-11-25 | PXD015335 | Pride
Glycoproteomics alzheimer's disease 
UnknownIntegrative glycoproteomics reveals protein N-glycosylation aberrations and glycoproteomic network alterations in Alzheimer's disease.
Not available
S-EPMC7852392 | biostudies-literature
UnknownSerum Glycoproteomics and Identification of Potential Mechanisms Underlying Alzheimer's Disease.
Not available
S-EPMC8684523 | biostudies-literature
ProteomicsIntegrated N- and O-glycoproteomics reveals site-specific glycosylation dysregulation in Alzheimer's disease
This study performed integrated intact N- and O-glycoproteomic profiling of human serum from normal controls (n=10), patients with mild cognitive impairment (MCI, n=10), and patients with Alzheimer's disease (AD, n=9). A total of 2,433 intact N-glycopeptides and 3,864 intact O-glycopeptides were ide...
ORGANISM(S): Homo Sapiens 
PXD082052 |
UnknownHuman brain glycoform coregulation network and glycan modification alterations in Alzheimer's disease.
Not available
S-EPMC10997212 | biostudies-literature
ProteomicsIntegrated Structural and Glycoproteomic Profiling Reveals Protein Conformational Remodeling and Biomarkers Across Alzheimer’s Disease Progression
Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and protein misfolding, yet the structural dynamics of proteins and their post-translational modifications during disease progression remain poorly understood. Here, we present an integrated structural and glycoproteomic anal...
ORGANISM(S): Homo sapiens (Human) 
2026-01-02 | PXD059280 | Pride
Sort   by:  
 Page size